drugset / Trial / NCT00382421

Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

NCT00382421 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

There is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), and, particularly, on a possible benefit of medical therapy in such patients. SWISSI 1 therefore recruits totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. Participants are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.

Timeline

Start
1992-02
Primary completion
—
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified — —
Subject Aspirin Small molecule — —
Subject Bisoprolol Other / unclassified — —
Subject Molsidomine Small molecule — —

Indications